The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage

Current Opinion in Hematology

Volumn 19, Issue 5, 2012, Pages 357-362

  Semple, John W ^a   Provan, Drew ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B lymphocytes; cytokines; immune thrombocytopenia; pathogenesis; T lymphocytes

Indexed keywords

B CELL ACTIVATING FACTOR; CD4 ANTIGEN; CD72 ANTIGEN; CELL PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 27; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RITUXIMAB; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANIN 1;

ANTIGEN PRESENTING CELL; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW; CELL DESTRUCTION; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LOW DRUG DOSE; MEGAKARYOCYTE; MONONUCLEAR CELL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIALYLATION; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ADMINISTRATION, INTRAVENOUS; AUTOIMMUNITY; B-LYMPHOCYTES; GAMMA-GLOBULINS; HUMANS; IMMUNITY, CELLULAR; OXIDATIVE STRESS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; T-LYMPHOCYTES;

EID: 84865435670     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283567541     Document Type: Review

References (66)

1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-186.
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386-2393.
3. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113:6511-6521.
4. Olsson B, Andersson PO, Jerna°s M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9:1123-1124. (Pubitemid 37173694)
5. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody-and CD8 + T cell-mediated responses that are differentially sensitive to therapy. Blood 2010; 115:1247-1253.
6. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a co-evolutionary perspective. Nat Rev Immunol 2009; 9:883-889.
7. Zho W, Restifo NP. TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10:248-256.
8. Tesmer LA. Th17 cells in human disease. Immunol Rev 2008; 223:87-113. (Pubitemid 351986173)
9. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-957. (Pubitemid 47300009)
10. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
11. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500.
12. David R. Regulatory T cells: fine-tuning TReg cells. Nat Rev Immunol 2009; 9:226-227.
13. Sollazzo D, Trabanelli S, Curti A, et al. Circulating CD4 +CD161 +CD196 + Th17 cells are not increased in immune thrombocytopenia. Haematologica 2011; 96:632-634.
14. Cao J, Li XQ, Chen C, et al. Imbalance of Th17/Treg cells ratio in peripheral blood of patients with immune thrombocytopenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011; 19:730-733.
15. Saitoh T, Tsukamoto N, Koiso H, et al. Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia. Eur J Haematol 2011; 87:253-258.
16. Rocha AM, Souza C, Rocha GA, et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 2011; 96:1560-1564.
17. Wang JD, Chang TK, Lin HK, et al. Reduced expression of transforming growth factor-b1 and correlated elevation of interleukin-17 and interferon-g in pediatric patients with chronic primary immune thrombocytopenia (ITP). Pediatr Blood Cancer 2011; 57:636-640.
18. Hu Y, Ma DX, Shan NN, et al. Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS One 2011; 6:e26522.
19. Cao J, Chen C, Zeng L, et al. Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia. Clin Immunol 2011; 141:121-123.
20. Cao J, Chen C, Li L, et al. Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. J Clin Immunol 2012; 32:523-529.
21. Chen X, Chen S, Li C, et al. Skewed T-cell subsets and enhanced macrophages phagocytosis in the spleen of patients with immune thrombocytopenia failing glucocorticoids. Int J Hematol 2011; 94:248-254.
22. Nishimoto T, Satoh T, Takeuchi T, et al. Critical role of CD4 +CD25 + regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol 2012; 40:279-289.
23. Aboul-Fotoh Lel-M, Abdel Raheem MM, El-Deen MA, Osman AM. Role of CD4 +CD25 + T cells in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2011; 33:81-85.
24. Shan NN, Wang X, Zhu XJ, et al. Role of IL-18/IL-18BP balance in spleen of patients with primary immune thrombocytopenia. Zhonghua Yi Xue Za Zhi 2011; 91:239-242.
25. Shan NN, Ji XB, Wang X, et al. In vitro recovery of Th1/Th2 balance in PBMCs from patients with immune thrombocytopenia through the actions of IL-18BPa/Fc. Thromb Res 2011; 128:e119-e124.
26. Li HY, Zhang DL,Ge J, et al. Elevated interleukin-27 enhances the polarization of Th1/Tc1 cells and the production of proinflammatory cytokines in primary immune thrombocytopenia. Hum Immunol 2012; 73:240-247.
27. Liu XG, Ren J, Yu Y, et al. Decreased expression of interleukin-27 in immune thrombocytopenia. Br J Haematol 2011; 153:259-267.
28. Ma L, Zhou Z, Wang H, et al. Increased expressions of DNA methyltransferases contribute to CD70 promoter hypomethylation and over expression of CD70 in ITP. Mol Immunol 2011; 48:1525-1531.
29. Ma L, Zhou Z, Jia H, et al. Effects of CD70 and CD11a in immune thrombocytopenia patients. J Clin Immunol 2011; 31:632-642.
30. Ma L, Zhou Z, Zhang D, et al. Bmi-1 regulates autoreactive CD4( +) T cell survival in immune thrombocytopenia patients. J Clin Immunol 2012; 32:505-513.
31. Saitoh T, Kasamatsu T, Inoue M, et al. Interleukin-10 gene polymorphism reflects the severity of chronic immune thrombocytopenia in Japanese patients. Int J Lab Hematol 2011; 33:526-532.
32. Sarpatwari A, Bussel JB, Ahmed M, et al. Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. Hematology 2011; 16:243-248.
33. Li H, Ge J, Zhao H, et al. Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population. Platelets 2011; 22:37-42.
34. Chen ZP, Gu DS, Zhou ZP, et al. Decreased expression of MBD2 and MBD4 gene and genomic-wide hypomethylation in patients with primary immune thrombocytopenia. Hum Immunol 2011; 72:486-491.
35. Zhou H, Qi AP, Li HY, et al. CD72 gene expression in immune thrombocytopenia. Platelets 2011; 22:1-8.
36. Rossi F, Mancusi S, Bellini G, et al. CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura. Haematologica 2011; 96:1883-1885.
37. Anis SK, Abdel Ghany EA, Mostafa NO, Ali AA. The role of PTPN22 gene polymorphism in childhood immune thrombocytopenic purpura. Blood Coagul Fibrinolysis 2011; 22:521-525.
38. Pehlivan M, Okan V, Sever T, et al. Investigation of TNF-alpha, TGF-beta 1, IL-10, IL-6, IFN-gamma, MBL, GPIA, and IL1A gene polymorphisms in patients with idiopathic thrombocytopenic purpura. Platelets 2011; 22:588-595.
39. Olsson B, Ridell B, Jerna° s M, Wadenvik H. Increased number of B-cells in the red pulp of the spleen in ITP. Ann Hematol 2012; 91:271-277.
40. Audia S, Samson M, Guy J, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011; 118:4394-4400.
41. Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol 2011; 93:91-98.
42. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 2009; 112:1147-1150.
43. Hoemberg M, Stahl D, Schlenke P, et al. The isotype of autoantibodies influences the phagocytosis of antibody-coated platelets in autoimmune thrombocytopenic purpura. Scand J Immunol 2011; 74:489-495.
44. Reheman A, Yang H, Zhu G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009; 113:1809-1817.
45. Yu H, Liu Y, Han J, et al. TLR7 regulates dendritic cell-dependent B-cell responses through BlyS in immune thrombocytopenic purpura. Eur J Haematol 2011; 86:67-74.
46. Yang Q, Xu S, Li X, et al. Pathway of Toll-like receptor 7/B cell activating factor/B cell activating factor receptor plays a role in immune thrombocytopenia in vivo. PLoS One 2011; 6:e22708.
47. Yang Q, Wang B, Yu H, et al. TLR7 promotes Th1 polarization in immune thrombocytopenia. Thromb Res 2011; 128:237-242.
48. Zhang B, Lo C, Shen L, et al. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood 2011; 117:4569-4579.
49. Imbach P, Barandum S, d'Appuzo V, et al. High-dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-1231.
50. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-486. (Pubitemid 32097072)
51. Leontyev D, Katsman Y, Branch DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcg receptor for the amelioration of ITP. Blood 2012; 119:5261-5264.
52. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-673. (Pubitemid 44201145)
53. Leontyev D, Katsman Y, Ma XZ, et al. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; doi: 10.1111/j.1537-2995.2011.03517.x. [Epub ahead of print]
54. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in antiplatelet antibody clearance via the FcRn receptor. Thromb Haemost 2002; 88:898-899. (Pubitemid 36018773)
55. Crow AR, Suppa SJ, Chen X, et al. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Blood 2011; 118:6403-6406.
56. Crow AR, Song S, Suppa SJ, et al. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Blood 2011; 117:971-974.
57. Winkler J, Kroiss S, Rand ML, et al. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol 2012; 156:508-515.
58. Leytin V, Mykhaylov S, Starkey AF, et al. IVIg inhibits anti-GPIIb-induced platelet apoptosis in a murine model of ITP. Br J Haematol 2006; 133:78-82.
59. Catani L, Sollazzo D, Ricci F, et al. The CD47 pathway is deregulated in human immune thrombocytopenia. Exp Hematol 2011; 39:486-494.
60. Jin CQ, Liu F, Dong HX, et al. Type 2 polarized immune response holds a major position in Epstein-Barr virus-related idiopathic thrombocytopenic purpura (EBV-ITP). Int J Lab Hematol 2012; 34:164-171.
61. Wang J, Zhang W, Nardi MA, Li Z. HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia. J Thromb Haemost 2011; 9:562-573.
62. Yang YJ, Yun GW, Song IC, et al. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med 2011; 26:449-454.
63. Saito A, Yokohama A, Osaki Y, et al. Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia. Eur J Haematol 2012; 88:340-349.
64. Liu XG, Ma SH, Sun JZ, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood 2011; 117:2061-2069.
65. Akyay A, Falay M, Ozturkmen S, et al. Hematogones in immune thrombocytopenic purpura: diagnostic implication. Turk J Pediatr 2011; 53:219-224.
66. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011; 9:262-273.